GSK's new drug brings hope of completely curing rectal cancer.
Global biopharmaceutical company GSK has just announced impressive results from phase 2 clinical trials of a new drug called Jemperli (dostarlimab). In this trial, Jemperli demonstrated incredible effectiveness in treating rectal cancer.
Jemperli is expected to open a new future for rectal cancer treatment.
Jemperli is expected to open a new future for rectal cancer treatment.
created, all 42 patients participating in the trial achieved complete clinical remission with no signs of tumor after treatment with Jemperli. In particular, among 24 patients followed for an average of 26.3 months, there was no case of cancer recurrence.
Jemperli is a monoclonal antibody drug that works by activating the body's immune system to kill cancer cells. This drug is expected to replace current standard treatments, including chemotherapy, radiotherapy and surgery, which causes many side effects and negatively affects patients' quality of life.
GSK said it will continue to study Jemperli in additional trials with other types of colorectal cancer. Although not yet widely approved worldwide, these promised results have opened a new direction in rectal cancer treatment, bringing hope to millions of patients globally.
apanese scientists have achieved a major breakthrough in their efforts to find a treatment for cervical cancer.
This breakthrough comes from a new study published by scientists in the journal Cell Reports Medicine at the end of 2023. Scientists said they are trying to use cytotoxic T lymphocytes rejuvenated (rejTs) to target HPV-specific antigens expressed in cervical cancer cells.
New breakthrough could help cure cervical cancer.
New breakthrough could help cure cervical cancer.
However, the press release on the study explains that a key problem with using this approach to create an off-the-shelf cancer therapy is that it is not “clinically feasible in terms of time.” and costs". So researchers at Juntendo University in Japan are starting to find ways to make it more feasible.
The team sought to solve one of the biggest hurdles when using rejT derived from iPSCs (a type of pluripotent stem cell generated from adult cells). Because those rejTs are generated using standard iPSCs rather than derived from the patient's own cells, they are often attractive to the body's natural killer (NK) cells and lymphocytes. Its T CD8+.
Therefore, finding a way to make the body's NK cells less attentive to rejT is important, and researchers at Juntendo University may have found a way to do that. To start, they removed all HLA class I antigens from the cells. Without those antigens, cells can hide from CD8+ T lymphocytes.
Watch More Image Part 2 >>>
A major breakthrough in the treatment of dangerous cancers in women - 23D illustration of cancer cells spreading to other parts of the body.
From there, they made a second modification that helped pave the way for an available cancer therapy. formation, they used CRISPR to restrict the expression of two specific HLA antigens. This allows the cells to completely avoid NK cells.
With these two modifications, the treatment may have a better chance of reaching the cells it really needs to target. During the trial, researchers obtained very promising results, and with further clinical testing, we may be closer than ever to finding a cure for cervical cancer. .
